ANTIMICROBIAL SUSCEPTIBILITY TO ORAL FLUROQUINOLONES AMONGST THE UROPATHOGENS ISOLATED FROM THE PAEDIATRIC POPULATION IN EASTERN INDIA
Main Article Content
Keywords
Urinary Tract Infection, Levofloxacin, Ciprofloxacin, Comparison
Abstract
Background: Inspite of increasing resistance to Fluroquinolones in India, this group may be a good therapeutic choice to manage Urinary Tract Infections, especially when phosphomycin, nitrofurantoin and cotrimoxazole have restricted indication.
Aim & Objective (s): Estimation of the magnitude of UTI in a tertiary care hospital in Eastern India & to compare uropathogenic susceptibility against levofloxacin and ciprofloxacin.
Material & Methods: The descriptive cross-sectional study was done from April 01, 2024 to June 30, 2024 with 142 culture positive uncomplicated UTI cases. Case selection was done as per predefined inclusion and exclusion criteria. Mid-stream urine was collected in proper aseptic manner and inoculated on Nutrient Agar Media, MacConkeys Agar media and Blood Agar media for bacterial isolation. Antimicrobial susceptibility testing was done by Kirby Bauer technique on Mueller Hinton Agar as per Clinical Laboratory Standards Institute guidelines.
Results: Age of majority of the cases is below 10 yrs with an average 4.8 yrs and There is no statistically significant difference in gender distribution. Escherichia coli may be considered as the leading uropathogenic bacteria (38%) in this study followed by Klebsiella pneumoniae (25%). Majority of the isolates is resistant to Ciprofloxacin (80%), on the contrary, sensitive to levofloxacin (48%).
Conclusion: Both being oral and broad spectrum, Levofloxacin and nitrofurantoin may be used as compatible therapeutic option and in comparison to Ciprofloxacin, Levofloxacin seems to be more effective against uropathogens in vitro.
References
2. Zusso M., Lunardi V., Franceschini D., Pagetta A., Lo R., Stifani S., et al. (2019). Ciprofloxacin and levofloxacin attenuate microglia inflammatory response via TLR4/NF-kB pathway. J. Neuroinflammation 16 (1), 148.
3. Rambaran K. A., Seifert C. F. (2019). Ciprofloxacin vs. levofloxacin for prophylaxis in recipients of hematopoietic stem cell transplantation. J. Oncol. Pharm. Pract. 25 (4), 884890.
4. Karampela I., Dalamaga M. (2020). Could respiratory fluoroquinolones, levofloxacin and moxifloxacin, prove to be beneficial as an adjunct treatment in COVID-19? Arch. Med. Res. 51 (7), 741742.
5. Cao D, Shen Y, Huang Y, Chen B, Chen Z, Ai J, Liu L, Yang L, Wei Q. Levofloxacin Versus Ciprofloxacin in the Treatment of Urinary Tract Infections: Evidence-Based Analysis. Front Pharmacol. 2021 Apr 8;12:658095.
6. Thompson D, Xu J, Ischia J, Bolton D. Fluoroquinolone resistance in urinary tract infections: Epidemiology, mechanisms of action and management strategies. BJUI Compass. 2024;5(1):511.
7. Thai T, Salisbury B, Zito P. Ciprofloxacin. [Updated 2021 Nov 15]. StatPearls [Internet] Treasure Island (FL): StatPearls Publishing. 2022.
8. Mohapatra S, Panigrahy R, Tak V, J V S, K C S, Chaudhuri S, Pundir S, Kocher D, Gautam H, Sood S, Das BK, Kapil A, Hari P, Kumar A, Kumari R, Kalaivani M, R A, Salve HR, Malhotra S, Kant S. Prevalence and resistance pattern of uropathogens from community settings of different regions: an experience from India. Access Microbiol. 2022 Feb 9;4(2):000321.
9. CLSI. Defining, Establishing, and Verifying Reference Intervals in the Clinical Laboratory; Approved Guideline, CLSI Document No. C28-A3. 3rd ed. United States: CLSI; 2008.
10. Tullus K, Shaikh N: Urinary tract infections in children. Lancet 395(10237):1659-1668, 2020.
11. Chakraborty, A., et al. (2018). Antimicrobial resistance patterns in uropathogens isolated from community-acquired and hospital-acquired infections in Eastern India. International Journal of Infectious Diseases, 74, 125-132.
12. Banerjee, S., et al. (2017). Extended-spectrum beta-lactamase producing Enterobacteriaceae in community-acquired urinary tract infections: A study from a tertiary care hospital in Eastern India. Journal of Clinical Microbiology, 55(2), 417-422.
13. Chao YS, Farrah K. Fluoroquinolones for the Treatment of Urinary Tract Infection: A Review of Clinical Effectiveness, Cost-Effectiveness, and Guidelines [Internet]. Ottawa (ON): Canadian Agency for Drugs and Technologies in Health; 2019 Apr 26.
14. Cao D, Shen Y, Huang Y, Chen B, Chen Z, Ai J, Liu L, Yang L, Wei Q. Levofloxacin Versus Ciprofloxacin in the Treatment of Urinary Tract Infections: Evidence-Based Analysis.
15. Afriyie DK, Adu LB, Dzradosi M, Amponsah SK, Ohene-Manu P, Manu-Ofei F. Comparative in vitro activity of ciprofloxacin and levofloxacin against isolated uropathogens in Ghana: a pilot study. Pan Afr Med J. 2018 Jul 5;30:194.
16. Xue Z, Xiang Y, Li Y, Yang Q. A systematic review and meta-analysis of levofloxacin and ciprofloxacin in the treatment of urinary tract infection. Ann Palliat Med 2021;10(9):9765-97
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All articles published in JPTCP are licensed under Copyright Creative Commons Attribution-NonCommercial 4.0 International License.
Dr. Pinaki Chattopadhyay
Associate Professor (microbiology), Department of Microbiology, Midnapore Medical College & Hospital, Paschim Medinipur, PIN Code-721101 (West Bengal)
Dr. Abhra Banerjee
Assistant Professor (Microbiology), Department of Microbiology and Multi Disciplinary Research Unit In charge, R G Kar Medical College & Hospital, Kolkata-700004 (West Bengal)
Dr. Sabyasachi Saha
Microbiologist, C&DST Laboratory (under NTEP), Midnapore Medical College & Hospital, Paschim Medinipur, PIN Code-721101 (West Bengal)
Dr. Jayashree Konar
Associate Professor (microbiology),Department of Microbiology, College of Medicine& Sagore Dutta Hospital, Kamarhati, Kolkata-700058 (West Bengal)